Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of an alarm symptom-based risk prediction score for localized oesophagogastric adenocarcinoma (VIOLA score).

ESMO open·2022
Same author

The faith of non-surveilled pancreatic cysts: a bicentric retrospective study.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2021
Same author

Tumor mutational burden and immune infiltrates in renal cell carcinoma and matched brain metastases.

ESMO open·2021
Same author

Applied precision cancer medicine in metastatic biliary tract cancer.

Hepatology international·2020
Same author

Applied Precision Cancer Medicine in Neuro-Oncology.

Scientific reports·2019
Same author

Role of ecology and phylogeny in determining tapeworm assemblages in skates (Rajiformes).

Journal of helminthology·2018
Same journal

Training in vascular trauma surgery for non-vascular surgeons: Vascular trauma surgery skills course.

European surgery : ACA : Acta chirurgica Austriaca·2023
Same journal

Remote training and evaluation of a simulator-based training course for complex endovascular procedures.

European surgery : ACA : Acta chirurgica Austriaca·2023
Same journal

Thoracoabdominal approach for traumatic diaphragmatic hernia in a hemodynamically unstable patient.

European surgery : ACA : Acta chirurgica Austriaca·2022
Same journal

Coping with a lack of evidence: living-donor kidney transplantation in the initial phase of the SARS-CoV-2 pandemic.

European surgery : ACA : Acta chirurgica Austriaca·2022
Same journal

Early detection of COVID-19 cholangiopathy using cholangioscopy-a case report of two critically ill patients.

European surgery : ACA : Acta chirurgica Austriaca·2022
Same journal

Impact of the COVID-19 pandemic on the training of general surgery residents: Surgical training and the COVID-19 pandemic.

European surgery : ACA : Acta chirurgica Austriaca·2022
See all related articles

Related Experiment Video

Updated: Mar 9, 2026

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

2.0K

Programmed death-ligand 1 expression in rectal cancer.

G Jomrich1, G R Silberhumer1, B Marian2

  • 1Department of Surgery, Medical University of Vienna, Spitalgasse 23, 1090 Vienna, Austria.

European Surgery : ACA : Acta Chirurgica Austriaca
|January 7, 2017
PubMed
Summary
This summary is machine-generated.

Programmed death ligand-1 (PD-L1) was not expressed in rectal cancer cells before or after neoadjuvant therapy in a study of 29 patients. Further research is needed to explore PD-L1

Keywords:
Neoadjuvant chemoradiationProgrammed death ligand 1Rectal cancerTotal mesorectal excisionTumor-infiltrating lymphocytes

More Related Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.2K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

11.1K

Related Experiment Videos

Last Updated: Mar 9, 2026

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

2.0K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.2K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

11.1K

Area of Science:

  • Oncology
  • Immunology

Background:

  • Colorectal cancer (CRC) is a leading cause of cancer death globally.
  • Rectal cancer (RC) accounts for approximately 30% of CRC cases, with a poor prognosis despite multimodal therapy.
  • Programmed cell death protein 1 (PD-1) and its ligand PD-L1 are key regulators of the anti-tumor immune response.

Purpose of the Study:

  • To investigate the expression of PD-L1 in rectal cancer.
  • To evaluate PD-L1 as a potential biomarker and therapeutic target in RC.
  • To analyze PD-L1 expression before and after neoadjuvant chemoradiation therapy.

Main Methods:

  • Retrospective analysis of 29 rectal cancer patients treated with neoadjuvant chemoradiation.
  • Immunohistochemistry was used to assess PD-L1 expression with two distinct anti-PD-L1 antibodies.

Main Results:

  • No PD-L1 expression was detected on cancer cells in any of the 29 patient specimens, neither before nor after neoadjuvant therapy.
  • Faint lymphohistiocytic staining for PD-L1 was observed in 17.24% of post-chemoradiation specimens using one of the antibodies.

Conclusions:

  • This study found no evidence of PD-L1 expression in rectal cancer cells following neoadjuvant chemoradiation.
  • The role of PD-L1 as a therapeutic target in rectal cancer requires further investigation.
  • Additional research is necessary to understand the potential of PD-L1 in rectal cancer treatment.